In last trading session, Corvus Pharmaceuticals Inc (NASDAQ:CRVS) saw 0.39 million shares changing hands with its beta currently measuring 1.03. Company’s recent per share price level of $9.42 trading at $0.69 or 7.90% at ring of the bell on the day assigns it a market valuation of $605.31M. That closing price of CRVS’s stock is at a discount of -6.16% from its 52-week high price of $10.00 and is indicating a premium of 86.2% from its 52-week low price of $1.30. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.0 million shares which gives us an average trading volume of 733.20K if we extend that period to 3-months.

For Corvus Pharmaceuticals Inc (CRVS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.12 in the current quarter.

Corvus Pharmaceuticals Inc (NASDAQ:CRVS) trade information

Upright in the green during last session for gaining 7.90%, in the last five days CRVS remained trading in the green while hitting it’s week-highest on Wednesday, 11/27/24 when the stock touched $9.42 price level, adding 0.84% to its value on the day. Corvus Pharmaceuticals Inc’s shares saw a change of 435.23% in year-to-date performance and have moved 14.32% in past 5-day. Corvus Pharmaceuticals Inc (NASDAQ:CRVS) showed a performance of 5.96% in past 30-days. Number of shares sold short was 2.93 million shares which calculate 3.82 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 12 to the stock, which implies a rise of 21.5% to its current value. Analysts have been projecting 7 as a low price target for the stock while placing it at a high target of 13. It follows that stock’s current price would jump 25.69% in reaching the projected high whereas dropping to the targeted low would mean a gain of 25.69% for stock’s current value.

Corvus Pharmaceuticals Inc (CRVS) estimates and forecasts

Statistics highlight that Corvus Pharmaceuticals Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 346.45% of value to its shares in past 6 months, showing an annual growth rate of -66.07% while that of industry is 17.60. Apart from that, the company came lowering its revenue forecast for fiscal year 2024.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 19.89% during past 5 years.

Corvus Pharmaceuticals Inc (NASDAQ:CRVS)’s Major holders

Insiders are in possession of 4.02% of company’s total shares while institution are holding 44.47 percent of that, with stock having share float percentage of 46.34%. Investors also watch the number of corporate investors in a company very closely, which is 44.47% institutions for Corvus Pharmaceuticals Inc that are currently holding shares of the company. ORBIMED ADVISORS LLC is the top institutional holder at CRVS for having 6.94 million shares of worth $12.64 million. And as of 2024-06-30, it was holding 14.1596 of the company’s outstanding shares.

The second largest institutional holder is SAMLYN CAPITAL, LLC, which was holding about 6.12 million shares on 2024-06-30. The number of shares represents firm’s hold over 12.4861 of outstanding shares, having a total worth of $11.14 million.